Related Experiment Videos
[Evaluation of cefpiramide in pediatrics]
Abstract:
Fundamental and clinical trials were carried out with cefpiramide (CPM) in pediatric infections. Results were as follows. CPM has a broad spectrum of activity against both Gram-positive and -negative microorganisms, including Pseudomonas. Half-lives of CPM were more prolonged than any others that have ever been reported on cephalosporin derivatives. The mean half-lives in the blood after infection were 4.76 hours and 4.14 hours, when the doses were 10 mg/kg and 20 mg/kg, respectively. The average recovery rates in the urine between 0 and 8 hours were 17.1% and 24.7%, when the intravenous doses were 10 mg/kg and 20 mg/kg, respectively. Thirty-two pediatric patients received CPM in doses ranging from 31.9 to 88.2 mg/kg divided mainly 2 times a day. They were respiratory tract infection in 23, urinary tract infection in 8, and SSSS in 1. The rate of satisfactory clinical response was 90.6%. Clinical side effect observed were mild diarrhea in 7 cases. Slight elevation of GOT and GPT were observed in 3 cases. All were considered to be minor.
Insights
Cefpiramide (CPM) demonstrates broad-spectrum antimicrobial activity in pediatric infections, including Pseudomonas. This cephalosporin derivative shows prolonged half-lives and a high clinical response rate with minor side effects.
Area of Science:
- Pharmacology
- Microbiology
- Pediatrics
Context:
- Pediatric infections pose significant health challenges.
- Novel antimicrobial agents are crucial for combating resistant pathogens.
- Cephalosporins are a widely used class of antibiotics.
Purpose:
- To evaluate the efficacy and safety of cefpiramide (CPM) in treating pediatric infections.
- To determine the pharmacokinetic profile of CPM in children.
Summary:
- Cefpiramide (CPM) exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including Pseudomonas.
- Pharmacokinetic studies revealed prolonged half-lives for CPM in pediatric patients (4.14-4.76 hours).
- In a clinical trial of 32 pediatric patients, CPM achieved a 90.6% satisfactory clinical response rate for respiratory tract, urinary tract infections, and Staphylococcal Scalded Skin Syndrome (SSSS), with mild, transient side effects observed.
Impact:
- Cefpiramide (CPM) represents a promising therapeutic option for pediatric infections.
- The favorable pharmacokinetic profile and high efficacy suggest CPM could be a valuable addition to the pediatric antibiotic armamentarium.
- Further research may explore CPM's role in managing specific pediatric infectious diseases.